OBJECTIVE
To test the performances of combining anti-CCP second generation (CCP2) with ACR 1987 classification criteria and to diagnose early RA in a community-based very early arthritis (VErA) patient cohort.
METHODS
The VErA cohort comprised 310 patients (median age 52 years; 68.1% women; median